INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517794, 'Vinblastine', 'Telaprevir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', 'DDInter', 1767317477, 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.', 'Metabolism', 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517795, 'Vinblastine', 'Troglitazone', 'Moderate', 'Coadministration with troglitazone may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by troglitazone.', 'DDInter', 1767317477, 'Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever troglitazone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517796, 'Vinblastine', 'Troleandomycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', 'DDInter', 1767317477, 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.', 'Metabolism', 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517797, 'Vinblastine', 'Typhoid vaccine (inactivated)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317477, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517798, 'Vitamin E', 'Vinblastine', 'Moderate', 'The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.', 'DDInter', 1767317477, 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.', 'Others', 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517799, 'Vincristine (liposome)', 'Aurothioglucose', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 1767317477, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517800, 'Vincristine (liposome)', 'Bacillus calmette-guerin substrain tice live antigen', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', 'DDInter', 1767317477, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517801, 'Vincristine (liposome)', 'Berotralstat', 'Moderate', 'Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.', 'DDInter', 1767317477, 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', 'Metabolism', 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517802, 'Bifidobacterium longum infantis', 'Vincristine (liposome)', 'Moderate', 'Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317477, 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.', 'Others', 'Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517803, 'Boceprevir', 'Vincristine (liposome)', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', 'DDInter', 1767317477, 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.', 'Metabolism', 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517804, 'Candida albicans', 'Vincristine (liposome)', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317477, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517805, 'Cerivastatin', 'Vincristine (liposome)', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 1767317477, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517806, 'Vincristine (liposome)', 'Vibrio cholerae CVD 103-HgR strain live antigen', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317477, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517807, 'Cinoxacin', 'Vincristine (liposome)', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 1767317477, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517808, 'Coccidioides immitis spherule', 'Vincristine (liposome)', 'Moderate', 'Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317477, 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', 'Others', 'Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517809, 'Efalizumab', 'Vincristine (liposome)', 'Moderate', 'The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', 'DDInter', 1767317477, 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.', 'Synergism', 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517810, 'Enoxacin', 'Vincristine (liposome)', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 1767317477, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517811, 'Grepafloxacin', 'Vincristine (liposome)', 'Moderate', 'Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.', 'DDInter', 1767317477, 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517812, 'Interferon alfa-2a, Recombinant', 'Vincristine (liposome)', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 1767317477, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517813, 'Interferon alfa-n1', 'Vincristine (liposome)', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 1767317477, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517814, 'Vincristine (liposome)', 'Ketoconazole', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', 'DDInter', 1767317477, 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.', 'Metabolism', 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517815, 'Vincristine (liposome)', 'Lomefloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 1767317477, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517816, 'Vincristine (liposome)', 'Lyme disease vaccine (recombinant OspA)', 'Moderate', 'The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317477, 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison''s disease).', 'Others', 'The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517817, 'Vincristine (liposome)', 'Nalidixic acid', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 1767317477, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517818, 'Vincristine (liposome)', 'Naxitamab', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 1767317477, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517819, 'Vincristine (liposome)', 'Radium Ra 223 dichloride', 'Moderate', 'The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.', 'DDInter', 1767317477, 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517820, 'Vincristine (liposome)', 'Rubella virus vaccine', 'Major', 'The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.', 'DDInter', 1767317477, 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.', 'Others', 'In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517821, 'Vincristine (liposome)', 'Pfizer-BioNTech Covid-19 Vaccine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317477, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517822, 'Vincristine (liposome)', 'Sodium phosphate, monobasic (p32)', 'Moderate', 'The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.', 'DDInter', 1767317477, 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.', 'Synergism', 'Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517823, 'Vincristine (liposome)', 'Somatrem', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', 'DDInter', 1767317477, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517824, 'Vincristine (liposome)', 'Sparfloxacin', 'Minor', 'Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.', 'DDInter', 1767317477, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517825, 'Vincristine (liposome)', 'Telaprevir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', 'DDInter', 1767317477, 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.', 'Metabolism', 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517826, 'Vincristine (liposome)', 'Troglitazone', 'Moderate', 'Coadministration with troglitazone may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by troglitazone.', 'DDInter', 1767317477, 'Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever troglitazone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517827, 'Vincristine (liposome)', 'Troleandomycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and/or P-glycoprotein may significantly increase the plasma concentrations of vinca alkaloids, which are substrates of both the hepatic microsomal isoenzyme and intracellular efflux transporter.', 'DDInter', 1767317477, 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible. Some authorities recommend avoiding concomitant use of vinca alkaloids during and for 2 weeks after treatment with itraconazole. Otherwise, conservative dosing of the antineoplastic should be considered, and the patient closely monitored for toxicity. Based on the known half-life of vinca alkaloids (24 to 48 hours), the time course of interaction is expected to be approximately 5 to 7 days. Patients should be advised to seek medical attention if they experience symptoms that could indicate neuro- or myelotoxicity, including constipation, abdominal pain or bloating, urinary retention, paresthesia, paralysis, muscle weakness, hearing loss, seizures, erratic blood pressure changes, unusual or excessive bleeding, easy bruising, pallor, fatigue, dizziness, lightheadedness, fever, chills, and sore throat. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the antineoplastic dosage is adjusted upward to the previous dosage.', 'Metabolism', 'Concomitant use of vinca alkaloids with potent CYP450 3A4 and/or P-glycoprotein inhibitors should be avoided if possible.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517828, 'Vincristine (liposome)', 'Typhoid vaccine (inactivated)', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 1767317477, 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517829, 'Vitamin E', 'Vincristine (liposome)', 'Moderate', 'The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.', 'DDInter', 1767317477, 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.', 'Others', 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517830, 'Anisindione', 'Vitamin E', 'Moderate', 'Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.', 'DDInter', 1767317477, 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517831, 'Vitamin E', 'Ardeparin', 'Moderate', 'Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.', 'DDInter', 1767317477, 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517832, 'Danaparoid', 'Vitamin E', 'Moderate', 'Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.', 'DDInter', 1767317477, 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517833, 'Dicoumarol', 'Vitamin E', 'Moderate', 'Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.', 'DDInter', 1767317477, 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517834, 'Doxorubicin (liposomal)', 'Vitamin E', 'Moderate', 'The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.', 'DDInter', 1767317477, 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.', 'Others', 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517835, 'Drotrecogin alfa', 'Vitamin E', 'Moderate', 'Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.', 'DDInter', 1767317477, 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517836, 'Efalizumab', 'Vitamin E', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517837, 'Iron protein succinylate', 'Vitamin E', 'Moderate', 'Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia.', 'DDInter', 1767317477, 'Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.', 'Antagonism', 'Patients receiving iron therapy for iron deficiency anemia should be monitored for potentially reduced hematologic response if vitamin E is administered concomitantly.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517838, 'Vitamin E', 'Melphalan flufenamide', 'Moderate', 'The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.', 'DDInter', 1767317477, 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.', 'Others', 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517839, 'Vitamin E', 'Muromonab', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517840, 'Vitamin E', 'Naxitamab', 'Moderate', 'The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.', 'DDInter', 1767317477, 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.', 'Others', 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517841, 'Vitamin E', 'Plicamycin', 'Moderate', 'The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.', 'DDInter', 1767317477, 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.', 'Others', 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517842, 'Vitamin E', 'Sulfinpyrazone', 'Moderate', 'Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.', 'DDInter', 1767317477, 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517843, 'Vitamin E', 'Tinzaparin', 'Moderate', 'Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.', 'DDInter', 1767317477, 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517844, 'Vitamin E', 'Uracil mustard', 'Moderate', 'The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.', 'DDInter', 1767317477, 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.', 'Others', 'Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517845, 'Anisindione', 'Drotrecogin alfa', 'Major', 'Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Treatment with drotrecogin alfa alone has been associated with serious and life-threatening bleeding episodes, including gastrointestinal, intracranial and retroperitoneal hemorrhage, although most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin time (PT).', 'DDInter', 1767317477, 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day). Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs. Continued use of other agents that may have contributed to the bleeding should be carefully assessed. Once adequate hemostasis is attained, drotrecogin alfa may be resumed if necessary.', 'Synergism', 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day).', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517846, 'Anistreplase', 'Drotrecogin alfa', 'Major', 'Concurrent administration of thrombolytic agents and drotrecogin alfa may increase the risk of serious or life-threatening bleeding complications due to additive or synergistic effects on the clotting cascade. Drotrecogin alfa inactivates blood clotting Factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin times (PT).', 'DDInter', 1767317477, 'When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.', 'Synergism', 'When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517847, 'Drotrecogin alfa', 'Ardeparin', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', 'DDInter', 1767317477, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517848, 'Drotrecogin alfa', 'Bromfenac', 'Major', 'Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT).', 'DDInter', 1767317477, 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia. Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs.', 'Synergism', 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517849, 'Drotrecogin alfa', 'Danaparoid', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', 'DDInter', 1767317477, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517850, 'Drotrecogin alfa', 'Dexfenfluramine', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', 'DDInter', 1767317477, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517851, 'Drotrecogin alfa', 'Dextran (-1)', 'Major', 'Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT).', 'DDInter', 1767317477, 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia. Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs.', 'Synergism', 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517852, 'Drotrecogin alfa', 'Dicoumarol', 'Major', 'Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Treatment with drotrecogin alfa alone has been associated with serious and life-threatening bleeding episodes, including gastrointestinal, intracranial and retroperitoneal hemorrhage, although most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin time (PT).', 'DDInter', 1767317477, 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day). Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs. Continued use of other agents that may have contributed to the bleeding should be carefully assessed. Once adequate hemostasis is attained, drotrecogin alfa may be resumed if necessary.', 'Synergism', 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day).', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517853, 'Hemin', 'Drotrecogin alfa', 'Moderate', 'Theoretically, hemin may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. Hemin has exhibited mild, transient anticoagulant effects during clinical studies.', 'DDInter', 1767317477, 'The use of hemin with concurrent anticoagulant therapy should be avoided. Caution is advised if hemin is used in combination with other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'The use of hemin with concurrent anticoagulant therapy should be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517854, 'Drotrecogin alfa', 'Phenylbutazone', 'Major', 'Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT).', 'DDInter', 1767317477, 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia. Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs.', 'Synergism', 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517855, 'Drotrecogin alfa', 'Plicamycin', 'Major', 'Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT).', 'DDInter', 1767317477, 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia. Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs.', 'Synergism', 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517856, 'Drotrecogin alfa', 'Salicylic acid (sodium)', 'Moderate', 'Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X, occasionally increasing the prothrombin time. While these effects are generally slight for most salicylates (except aspirin) at recommended dosages, they may be of clinical significance when combined with the inhibitory effects of anticoagulants on the clotting cascade. Moreover, salicylates are known to cause dose-related gastrointestinal bleeding, which may be complicated by anticoagulant therapy.', 'DDInter', 1767317477, 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.', 'Synergism', 'Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517857, 'Drotrecogin alfa', 'Streptokinase', 'Major', 'Concurrent administration of thrombolytic agents and drotrecogin alfa may increase the risk of serious or life-threatening bleeding complications due to additive or synergistic effects on the clotting cascade. Drotrecogin alfa inactivates blood clotting Factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin times (PT).', 'DDInter', 1767317477, 'When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.', 'Synergism', 'When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517858, 'Drotrecogin alfa', 'Sulfinpyrazone', 'Major', 'Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Treatment with drotrecogin alfa alone has been associated with serious and life-threatening bleeding episodes, including gastrointestinal, intracranial and retroperitoneal hemorrhage, although most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin time (PT).', 'DDInter', 1767317477, 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day). Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs. Continued use of other agents that may have contributed to the bleeding should be carefully assessed. Once adequate hemostasis is attained, drotrecogin alfa may be resumed if necessary.', 'Synergism', 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day).', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517859, 'Drotrecogin alfa', 'Tinzaparin', 'Major', 'Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.', 'DDInter', 1767317477, 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.', 'Synergism', 'In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517860, 'Drotrecogin alfa', 'Tositumomab', 'Major', 'Coadministration of tositumomab and iodine I 131 tositumomab with drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Tositumomab and iodine I 131 tositumomab alone can cause severe or life-threatening thrombocytopenia.', 'DDInter', 1767317477, 'Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously. Close clinical and laboratory observation for bleeding complications is recommended during and after the therapeutic regimen.', 'Synergism', 'Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517861, 'Drotrecogin alfa', 'Urokinase', 'Major', 'Concurrent administration of thrombolytic agents and drotrecogin alfa may increase the risk of serious or life-threatening bleeding complications due to additive or synergistic effects on the clotting cascade. Drotrecogin alfa inactivates blood clotting Factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin times (PT).', 'DDInter', 1767317477, 'When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.', 'Synergism', 'When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who have recently (within 3 days) received thrombolytic agents.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517862, 'Yohimbine', 'Morphine (liposomal)', 'Minor', 'double-blind, placebo-controlled study of patients with postoperative dental pain found that while yohimbine itself did not affect pain, the overall analgesic effect of morphine was significantly enhanced in the presence of yohimbine. The mechanism of interaction is unknown. Additional research involving other pain states is needed.', 'DDInter', 1767317477, '-', 'Synergism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517863, 'Yohimbine', 'Troglitazone', 'Moderate', 'Coadministration with troglitazone may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by troglitazone.', 'DDInter', 1767317477, 'Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever troglitazone is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if troglitazone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517864, 'Efalizumab', 'Zinc chloride', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517865, 'Zinc chloride', 'Melphalan', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517866, 'Zinc chloride', 'Melphalan flufenamide', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517867, 'Zinc chloride', 'Muromonab', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517868, 'Zinc chloride', 'Naxitamab', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517869, 'Zinc chloride', 'Oxytetracycline', 'Moderate', 'INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 1767317477, 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.', 'Absorption', 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517870, 'Cinoxacin', 'Zinc gluconate', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 1767317477, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517871, 'Dolutegravir', 'Zinc gluconate', 'Major', 'INTERVAL: Coadministration with medications or supplements containing polyvalent cations such as zinc may decrease the plasma concentrations of integrase strand transfer inhibitors (INSTIs). The proposed mechanism involves chelation of the INSTI by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 1767317477, 'If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.', 'Absorption', 'If concomitant use is required, monitor for virologic efficacy and administer the INSTI at least 2 hours before or 6 hours after products containing polyvalent cations such as zinc.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517872, 'Efalizumab', 'Zinc gluconate', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517873, 'Enoxacin', 'Zinc gluconate', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 1767317477, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517874, 'Grepafloxacin', 'Zinc gluconate', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 1767317477, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517875, 'Iron protein succinylate', 'Zinc gluconate', 'Minor', 'Iron and zinc may reduce each other''s absorption when they are coadministered orally. The mechanism of interaction is unknown. In clinical studies, concurrent supplementation with iron and zinc was associated with reduced efficacy in improving the growth and iron and zinc status of malnourished infants compared to supplementation with either one alone. In any case, the clinical significance is probably minimal in healthy individuals. However, monitoring for reduced therapeutic response may be advisable in malnourished patients. Limited data suggest that the magnitude of the interaction may be lessened by separating the times of administration of each by 12 hours.', 'DDInter', 1767317477, '-', 'Absorption', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517876, 'Zinc gluconate', 'Lomefloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 1767317477, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517877, 'Zinc gluconate', 'Melphalan', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517878, 'Zinc gluconate', 'Melphalan flufenamide', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517879, 'Zinc gluconate', 'Muromonab', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517880, 'Zinc gluconate', 'Nalidixic acid', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 1767317477, 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', 'When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517881, 'Zinc gluconate', 'Naxitamab', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', 1767317477, '-', 'Antagonism', '-', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517882, 'Zinc gluconate', 'Oxytetracycline', 'Moderate', 'INTERVAL: The bioavailability of oral tetracyclines may be significantly decreased during concurrent administration with zinc-containing products. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the zinc cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 1767317477, 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours. Doxycycline may be an appropriate alternative, since its absorption may not be significantly affected by zinc coadministration.', 'Absorption', 'Patients receiving an oral tetracycline in combination with zinc-containing products should be advised to separate the times of administration by at least three to four hours.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517883, 'Zinc gluconate', 'Sparfloxacin', 'Moderate', 'INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.', 'DDInter', 1767317477, 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', 'Absorption', 'When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517884, 'Zinc gluconate', 'Tiludronic acid', 'Moderate', 'INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.', 'DDInter', 1767317477, 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', 'Absorption', 'Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517885, 'Goserelin', 'Gefitinib', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517886, 'Goserelin', 'Zoledronic acid', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517887, 'Goserelin', 'Allopurinol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517888, 'Goserelin', 'Montelukast', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517889, 'Goserelin', 'Duloxetine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517890, 'Goserelin', 'Lenalidomide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517891, 'Goserelin', 'Simvastatin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517892, 'Goserelin', 'Tamsulosin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517893, 'Goserelin', 'Misoprostol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517894, 'Goserelin', 'Fulvestrant', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517895, 'Goserelin', 'Exemestane', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517896, 'Goserelin', 'Rosuvastatin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517897, 'Goserelin', 'Capecitabine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517898, 'Goserelin', 'Dutasteride', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517899, 'Goserelin', 'Tiotropium', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517900, 'Goserelin', 'Fluticasone', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517901, 'Desmopressin', 'Allopurinol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517902, 'Desmopressin', 'Lactulose', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517903, 'Desmopressin', 'Simvastatin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517904, 'Ezetimibe', 'Desmopressin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517905, 'Desmopressin', 'Levetiracetam', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517906, 'Folic acid', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517907, 'Cyclosporine', 'Lorazepam', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517908, 'Cyclosporine', 'Bortezomib', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517909, 'Cyclosporine', 'Tramadol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517910, 'Cyclosporine', 'Oseltamivir', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517911, 'Cyclosporine', 'Torasemide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517912, 'Cyclosporine', 'Moxifloxacin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517913, 'Gadodiamide', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517914, 'Cyclosporine', 'Pregabalin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517915, 'Cyclosporine', 'Temazepam', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517916, 'Dapsone', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517917, 'Cyclosporine', 'Metoprolol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517918, 'Cyclosporine', 'Ropinirole', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517919, 'Isradipine', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517920, 'Cyclosporine', 'Topiramate', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517921, 'Cyclosporine', 'Lidocaine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517922, 'Cyclosporine', 'Travoprost', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517923, 'Cyclosporine', 'Morphine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517924, 'Cyclosporine', 'Valproic acid', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517925, 'Cyclosporine', 'Piperacillin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517926, 'Fluorometholone', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517927, 'Hydromorphone', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517928, 'Ethambutol', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517929, 'Cyclosporine', 'Metformin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517930, 'Cyclosporine', 'Olanzapine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517931, 'Cyclosporine', 'Minoxidil', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517932, 'Cyclosporine', 'Mirtazapine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517933, 'Cyclosporine', 'Timolol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517934, 'Cyclosporine', 'Rosiglitazone', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517935, 'Cyclosporine', 'Pramipexole', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517936, 'Cyclosporine', 'Phenoxymethylpenicillin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517937, 'Cyclosporine', 'Methocarbamol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517938, 'Cyclosporine', 'Zolpidem', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517939, 'Famciclovir', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517940, 'Cyclosporine', 'Prochlorperazine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517941, 'Gemcitabine', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517942, 'Cyclosporine', 'Meperidine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517943, 'Cyclosporine', 'Loratadine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517944, 'Cyclosporine', 'Acitretin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517945, 'Cyclosporine', 'Montelukast', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517946, 'Duloxetine', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517947, 'Cyclosporine', 'Lenalidomide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517948, 'Cyclosporine', 'Raloxifene', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517949, 'Cyclosporine', 'Sotalol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517950, 'Haloperidol', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517951, 'Cyclosporine', 'Cisplatin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517952, 'Gadoversetamide', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517953, 'Cyclosporine', 'Nortriptyline', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517954, 'Fluorouracil', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517955, 'Cyclosporine', 'Pyridostigmine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517956, 'Cyclosporine', 'Lamotrigine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517957, 'Hydroxyzine', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517958, 'Cyclosporine', 'Propranolol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517959, 'Cyclosporine', 'Atropine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517960, 'Cyclosporine', 'Lactulose', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517961, 'Cyclosporine', 'Nizatidine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517962, 'Doxazosin', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517963, 'Cyclosporine', 'Labetalol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517964, 'Cyclosporine', 'Linezolid', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517965, 'Cyclosporine', 'Nystatin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517966, 'Cyclosporine', 'Latanoprost', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517967, 'Cyclosporine', 'Trazodone', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517968, 'Cyclosporine', 'Sumatriptan', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517969, 'Cyclosporine', 'Tamoxifen', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517970, 'Cyclosporine', 'Midazolam', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517971, 'Cyclosporine', 'Tizanidine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517972, 'Cyclosporine', 'Nitrofurantoin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517973, 'Cyclosporine', 'Tamsulosin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517974, 'Cyclosporine', 'Lamivudine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517975, 'Cyclosporine', 'Paroxetine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517976, 'Cyclosporine', 'Adefovir dipivoxil', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517977, 'Imiquimod', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517978, 'Cyclosporine', 'Nitroglycerin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517979, 'Cyclosporine', 'Risperidone', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517980, 'Deferoxamine', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517981, 'Cyclosporine', 'Scopolamine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517982, 'Cyclosporine', 'Tretinoin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517983, 'Dolasetron', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517984, 'Cyclosporine', 'Tetracycline', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517985, 'Cyclosporine', 'Potassium chloride', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517986, 'Cyclosporine', 'Olopatadine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517987, 'Cyclosporine', 'Pentoxifylline', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517988, 'Cyclosporine', 'Ribavirin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517989, 'Cyclosporine', 'Propofol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517990, 'Diazepam', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517991, 'Cyclosporine', 'Oxazepam', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517992, 'Cyclosporine', 'Nalbuphine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517993, 'Cyclosporine', 'Penicillamine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517994, 'Cyclosporine', 'Risedronic acid', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517995, 'Granisetron', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517996, 'Cyclosporine', 'Triazolam', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517997, 'Cyclosporine', 'Ondansetron', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517998, 'Cyclosporine', 'Bimatoprost', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1517999, 'Cyclosporine', 'Zonisamide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518000, 'Cyclosporine', 'Paricalcitol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518001, 'Famotidine', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518002, 'Cyclosporine', 'Misoprostol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518003, 'Cyclosporine', 'Salmeterol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518004, 'Fexofenadine', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518005, 'Cyclosporine', 'Carboplatin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518006, 'Cyclosporine', 'Zaleplon', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518007, 'Desloratadine', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518008, 'Cyclosporine', 'Methyldopa', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518009, 'Dipyridamole', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518010, 'Cyclosporine', 'Auranofin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518011, 'Gabapentin', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518012, 'Hydroxyurea', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518013, 'Cyclosporine', 'Cinacalcet', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518014, 'Cyclosporine', 'Minocycline', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518015, 'Isosorbide mononitrate', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518016, 'Cyclosporine', 'Phylloquinone', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518017, 'Cyclosporine', 'Mercaptopurine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518018, 'Cyclosporine', 'Thalidomide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518019, 'Gatifloxacin', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518020, 'Fluocinonide', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518021, 'Cyclosporine', 'Oxybutynin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518022, 'Cyclosporine', 'Promethazine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518023, 'Fludarabine', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518024, 'Cyclosporine', 'Tegaserod', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518025, 'Cyclosporine', 'Pilocarpine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518026, 'Iloprost', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518027, 'Cyclosporine', 'Atovaquone', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518028, 'Cyclosporine', 'Pioglitazone', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518029, 'Cyclosporine', 'Terazosin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518030, 'Cyclosporine', 'Calcium chloride', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518031, 'Cyclosporine', 'Ofloxacin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518032, 'Cyclosporine', 'Orphenadrine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518033, 'Ifosfamide', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518034, 'Cyclosporine', 'Brinzolamide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518035, 'Flecainide', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518036, 'Cyclosporine', 'Zopiclone', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518037, 'Cyclosporine', 'Levetiracetam', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518038, 'Cyclosporine', 'Nadolol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518039, 'Cyclosporine', 'Levobunolol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518040, 'Finasteride', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518041, 'Cyclosporine', 'Ketamine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518042, 'Cyclosporine', 'Sevoflurane', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518043, 'Cyclosporine', 'Varenicline', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518044, 'Hydralazine', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518045, 'Cyclosporine', 'Sodium bicarbonate', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518046, 'Cyclosporine', 'Tiotropium', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518047, 'Cyclosporine', 'Thiotepa', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518048, 'Cyclosporine', 'Vitamin D', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518049, 'Cyclosporine', 'Clobetasol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518050, 'Fluticasone', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518051, 'Hydrocortisone butyrate', 'Cyclosporine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518052, 'Cyclosporine', 'Loteprednol etabonate', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518053, 'Bortezomib', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518054, 'Sucralfate', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518055, 'Sorafenib', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518056, 'Zoledronic acid', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518057, 'Allopurinol', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518058, 'Octreotide', 'Montelukast', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518059, 'Cisplatin', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518060, 'Caspofungin', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518061, 'Bosentan', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518062, 'Octreotide', 'Lactulose', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518063, 'Simvastatin', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518064, 'Octreotide', 'Nystatin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518065, 'Tamsulosin', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518066, 'Rosuvastatin', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518067, 'Valganciclovir', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518068, 'Fluticasone', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518069, 'Cyclosporine', 'Cyanocobalamin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518070, 'Cyanocobalamin', 'Octreotide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518071, 'Folic acid', 'Cyanocobalamin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518072, 'Cyanocobalamin', 'Pravastatin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518073, 'Fluvoxamine', 'Cyanocobalamin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518074, 'Cyanocobalamin', 'Valsartan', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518075, 'Cyanocobalamin', 'Ramipril', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518076, 'Flunisolide', 'Cyanocobalamin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518077, 'Cyanocobalamin', 'Lorazepam', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518078, 'Cyanocobalamin', 'Bortezomib', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518079, 'Cyanocobalamin', 'Tramadol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518080, 'Fluconazole', 'Cyanocobalamin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518081, 'Cyanocobalamin', 'Oseltamivir', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518082, 'Erythromycin', 'Cyanocobalamin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518083, 'Cyanocobalamin', 'Sildenafil', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518084, 'Cyanocobalamin', 'Torasemide', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518085, 'Cyanocobalamin', 'Moxifloxacin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518086, 'Glimepiride', 'Cyanocobalamin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518087, 'Cyanocobalamin', 'Lovastatin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518088, 'Cyanocobalamin', 'Pregabalin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518089, 'Cyanocobalamin', 'Temazepam', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518090, 'Cyanocobalamin', 'Mesalazine', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518091, 'Dapsone', 'Cyanocobalamin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518092, 'Doxycycline', 'Cyanocobalamin', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1518093, 'Cyanocobalamin', 'Metoprolol', 'Unknown', 'None', 'DDInter', 1767317477, '-', NULL, '-', NULL, NULL, 'Unknown', 'pharmacodynamic');
